✕
Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
 简体中文
(Simplified Chinese) 繁體中文
(Traditional Chinese)
FOCUSED ON OUTCOMES
Lighting the way to help improve patient care.

Improving global health depends on focused and effective research.

MediBeacon is focused on technology advances that make the use of fluorescent tracer agent-based transdermal measurement systems an important factor in the delivery of superior medical care.

Our objectives are to develop tools to aid in the understanding of disease and the development of interventions which can slow or arrest disease progression. More efficient research holds the promise of improving the likelihood that the most effective and appropriate treatments are available to patients as soon as possible.

NEPHROLOGY*

Slowing the progression to End Stage Renal Disease (ESRD) is critical to prolonging human lifespan and improving the quality of life for those who are either susceptible to kidney disease or who have kidney disease.

Chronic kidney disease often develops slowly and with few symptoms. Many people don’t realize they’re sick until the disease is advanced.

  • More than 1 in 7 adults in the US are estimated to have Chronic Kidney Disease (CKD).
  • Approximately 1 in 3 adults with diabetes (and 1 in 5 adults with high blood pressure) may have CKD.
  • As many as 9 in 10 adults with CKD do not know they have it.
  • About 1 in 3 adults with severe CKD do not know they have it.
– Centers for Disease Control and Prevention (CDC) CKD in the United States, 2023 CKD-Factsheet-H.pdf
GASTROENTEROLOGY*

There is growing research that connects abnormal gastrointestinal permeability to specific inflammatory bowel diseases. Peer-reviewed publications have continued to increase exponentially in this area. In 2018 alone, there were over 800 peer-reviewed publications.

Increasing evidence points to abnormal gut permeability as a “leading indicator” of inflammation.

- BMC Gastroenterology, Stephan Bischoff et al.,
Intestinal permeability - a new target for disease prevention and therapy, 2014
OPHTHALMOLOGY*

Diagnosing and monitoring vasculature leakage in the eye is a key factor in diagnosing and monitoring various disease states including Diabetic Retinopathy, Macular Degeneration and Retinal Vasculitis.

SURGERY*

Ureteral injury is one of the most serious complications of gynecologic surgery. Ureteral injuries are often associated with significant morbidity, especially when recognized postoperatively. Injuries to the urinary tract are the most common cause for legal action against gynecologic surgeons.

- Medscape Reference, Sandip P Vasavada, MD et al.,
Ureteral injury during gynecologic surgery, March 13, 2013

The use of fluorescent tracer agent-based systems has the potential to aid in the mitigation of serious complications during gynecologic and other abdominal surgeries.
IN DISCOVERY

Potential medical applications for fluorescent tracer agent-based systems are wide ranging and target important unmet patient needs.

United States
MediBeacon Inc.
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 269-5808

Germany
MediBeacon GmbH
Cubex41
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
P: +49 (0)621-150283-15

Greater China
(Exclusive Commercial Partner)
Huadong Medicine Co., Ltd
Telephone: 4008-269-985
+86-(0)571-89908581
Zip: 310011
Address: No.866. Moganshan Road, Hangzhou, Zhejiang Province, China
Email: info@eastchinapharm.com

Science How it Works R&D Platform Product Pipeline Patent Estate Preclinical Clinical Focus Areas Nephrology Gastroenterology Ophthalmology Surgery In Discovery
Publications MediBeacon Publications Preclinical Publications Industry Literature Company History People By the Numbers Quality Commitment News/Media Contact Get Updates Investors General Questions

*MediBeacon products are in various stages of clinical development and not yet approved for human use.

Terms and Conditions | Privacy Policy | © 2024 MediBeacon All Rights Reserved.

COOKIE CONSENT: We use cookies and similar technologies to recognize your repeat visits and preferences, as well as to analyze traffic, among other things. To learn more about cookies, view our Privacy Policy. By clicking “I Accept” on this banner, or using our site, you consent to the use of cookies unless you have disabled them.